Clinical Trial Update: A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis [Phase 1]

View source ↗

Summary

This Phase 1 dose-escalation study reports on the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• TG101348 (fedratinib)

Snippet

Sponsor: TargeGen | Conditions: Myelofibrosis | Phase 1 | Status: COMPLETED